**SUPPLEMENTARY TABLE 1.** *Vaginal pH**at baseline and week 12 (LOCF)*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **E4 2.5 mg** | **E4 5 mg** | **E4 10 mg** | **E4 15 mg** | **Placebo** |
|  | ***n* = 53** | ***n* = 47** | ***n* = 53** | ***n* = 49** | ***n* = 55** |
| **Baseline, mean (SD)** | 4.59 (0.71) | 4.81 (0.92) | 4.71 (0.74) | 4.58 (0.64) | 4.60 (0.63) |
|  |  |  |  |  |  |
| **Week 12** |  |  |  |  |  |
| Change from baseline, mean (SD) | -0.16(0.75) | -0.22(1.17) | -0.08(0.78) | -0.12(0.55) | 0.12(0.72) |
| Change from baseline, LS mean(95% CI) | -0.23(-0.41 to -0.05) | -0.05(-0.23 to 0.14) | -0.06(-0.24 to 0.11) | -0.21(-40.0 to -0.02) | -0.01(-0.18 to 0.16) |
| *P value vs placeboa* | *0.23* | *0.99* | *0.98* | *0.34* |  |

CI, confidence interval; LOCF, last observation carried forward; LS, least square; SD, standard deviation.

a Pairwise comparisons vs placebo (with Dunnett’s adjustment for multiple comparisons) using an ANCOVA with treatment and center as fixed effects and baseline as covariate.